|
1）Kashiwagi H, Tomiyama Y. Pathophysiology and management of primary immune thrombocytopenia. Int J Hematol. 2013; 98: 24-33
|
|
|
|
2）Roark JH, Bussel JB, Cines DB, et al. Genetic analysis of autoantibodies in idiopathic thrombocytopenic purpura reveals evidence of clonal expansion and somatic mutation. Blood. 2002; 100: 1388-98
|
|
|
|
|
|
3）Kiyomizu K, Kashiwagi H, Nakazawa T, et al. Recognition of highly restricted regions in the β-propeller domain of αIIb by platelet-associated anti-αIIbβ3 autoantibodies in primary immune thrombocytopenia. Blood. 2012; 120: 1499-509
|
|
|
|
|
|
4）Kuwana M, Kaburaki J, Ikeda Y. Autoreactive T cells to platelet GPIIb-IIIa in immune thrombocytopenic purpura. Role in production of anti-platelet autoantibody. J Clin Invest. 1998; 102: 1393-402
|
|
|
|
|
|
5）Wang JD, Chang TK, Lin HK, et al. Reduced expression of transforming growth factor-b1 and correlated elevation of interleukin-17 and interferon-g in pediatric patients with chronic primary immune thrombocytopenia (ITP). Pediatr Blood Cancer. 2011; 57: 636-40
|
|
|
|
|
|
6）Saitoh T, Tsukamoto N, Koiso H, et al. Interleukin-17F gene polymorphism in patients with chronic immune thrombocytopenia. Eur J Haematol. 2011; 87: 253-8
|
|
|
|
|
|
7）Doreau A, Belot A, Bastid J, et al. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol. 2009; 10: 778-85
|
|
|
|
|
|
8）Zhu XJ, Shi Y, Peng J, et al. The effects of BAFF and BAFF-R-Fc fusion protein in immune thrombocytopenia. Blood. 2009; 114: 5362-7
|
|
|
|
|
|
9）Kuwana M, Okazaki Y, Ikeda Y. Splenic macrophages maintain the anti-platelet autoimmune response via uptake of opsonized platelets in patients with immune thrombocytopenic purpura. J Thromb Haemost. 2009; 7: 322-9
|
|
|
|
|
|
10）McKenzie SE, Taylor SM, Malladi P, et al. The role of the human Fc receptor Fc gamma RIIA in the immune clearance of platelets: a transgenic mouse model. J Immunol. 1999; 162: 4311-8
|
|
|
|
|
|
11）Biburger M, Aschermann S, Schwab I, et al. Monocyte subsets responsible for immunoglobulin G-dependent effector functions in vivo. Immunity. 2011; 35: 932-44
|
|
|
|
|
|
12）Cooper N, Stasi R, Cunningham-Rundles S, et al. Platelet-associated antibodies, cellular immunity and FCGR3a genotype influence the response to rituximab in immune thrombocytopenia. Br J Haematol. 2012; 158: 539-47
|
|
|
|
|
|
13）Asahi A, Nishimoto T, Okazaki Y, et al. Helicobacter pylori eradication shifts monocyte Fc gamma receptor balance toward inhibitory Fc gamma RIIB in immune thrombocytopenic purpura patients. J Clin Invest. 2008; 118: 2939-49
|
|
|
|
|
|
14）Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science. 2001; 291: 484-6
|
|
|
|
|
|
15）Leontyev D, Katsman Y, Branch DR. Mouse background and IVIG dosage are critical in establishing the role of inhibitory Fcγ receptor for the amelioration of experimental ITP. Blood. 2012; 119: 5261-4
|
|
|
|
|
|
16）Olsson B, Andersson PO, Jernås M, et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med. 2003; 9: 1123-4
|
|
|
|
|
|
17）Chow L, Aslam R, Speck ER, et al. A murine model of severe immune thrombocytopenia is induced by antibody-and CD8＋ T cell-mediated responses that are differentially sensitive to therapy. Blood. 2010; 115: 1247-53
|
|
|
|
|
|
18）Houwerzijl EJ, Blom NR, van der Want JJ, et al. Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood. 2004; 103: 500-6
|
|
|
|
|
|
19）Yang L, Wang L, Zhao CH, et al. Contributions of TRAIL-mediated megakaryocyte apoptosis to impaired megakaryocyte and platelet production in immune thrombocytopenia. Blood. 2010; 116: 4307-16
|
|
|
|
|
|
20）Sakaguchi S. Naturally arising Foxp3-expressing CD25＋CD4＋ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. 2005; 6: 345-52
|
|
|
|
|
|
21）Bao W, Bussel JB, Heck S, et al. Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood. 2010; 116: 4639-45
|
|
|
|
|
|
22）Nishimoto T, Satoh T, Takeuchi T, et al. Critical role of CD4(+)CD25(+) regulatory T cells in preventing murine autoantibody-mediated thrombocytopenia. Exp Hematol. 2012; 40: 279-89
|
|
|
|
|
|
23）Aslam R, Hu Y, Gebremeskel S, et al. Thymic retention of CD4＋CD25＋FoxP3＋ T regulatory cells is associated with their peripheral deficiency and thrombocytopenia in a murine model of immune thrombocytopenia. Blood. 2012; 120: 2127-32
|
|
|
|
|
|
24）Stasi R, Cooper N, Del Poeta G, et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood. 2008; 112: 1147-50
|
|
|
|
|